scholarly journals Combination therapy of anabolic and nonbisphosphonates antiresorptive agents for the treatment of osteoporosis

Medicine ◽  
2017 ◽  
Vol 96 (52) ◽  
pp. e9534 ◽  
Author(s):  
Shenghan Lou ◽  
Lifan Wang ◽  
Yiwen Wang ◽  
Yunduo Jiang ◽  
Jingwei Liu ◽  
...  
Keyword(s):  
Combination Therapy ◽  
Treatment Of Osteoporosis ◽  
Antiresorptive Agents

scholarly journals The use of PTH in the treatment of osteoporosis

2010 ◽  
Vol 54 (2) ◽  
pp. 213-219 ◽  
Author(s):  
Victória Z. Cochenski Borba ◽  
Nádila Cecyn Pietszkowski Mañas
Keyword(s):  
Parathyroid Hormone ◽  
Bone Density ◽  
Adverse Effects ◽  
Combination Therapy ◽  
Biochemical Markers ◽  
Osteoporosis Treatment ◽  
Antiresorptive Therapy ◽  
Treatment Of Osteoporosis ◽  
Antiresorptive Agents ◽  
Anabolic Treatment

Anabolic drugs have recently widened therapeutic options in osteoporosis treatment, as they influence processes associated with bone formation to a greater extent and earlier than bone reabsortion. They positively affect a number of skeletal properties besides bone density, as intermittent administration of parathyroid hormone (PTH) results in an increase in the number and activity of osteoblasts leading to an increase in bone mass and improvement in skeletal architecture at both the trabecular and cortical bone. Human recombinant parathyroid hormone (hrPTH 1-84) and human recombinant PTH peptide 1-34 (teriparatide) belong to this group. The objective of this paper is to review PTH actions, benefits and adverse effects, action on biochemical markers, combination therapy with antiresorptive agents, impact of antiresorptive therapy prior to anabolic treatment, sequential treatment, and effect on glucocorticoid-induced osteoporosis.

Bisphosphonates in Orthopedics: Evidence-based Review of Indications and Adverse Effects

2016 ◽  
Vol 50 (2) ◽  
pp. 75-85 ◽  
Author(s):  
Nitesh Gahlot ◽  
Uttam Chand Saini
Keyword(s):  
Adverse Effects ◽  
Metastatic Bone Disease ◽  
Evidence Based ◽  
Important Class ◽  
Pharmacokinetics And Pharmacodynamics ◽  
Potent Effect ◽  
Treatment Of Osteoporosis ◽  
Antiresorptive Agents ◽  
Orthopedic Applications ◽  
Pediatric Disorders

ABSTRACT Bisphosphonates (BPs) are clinically the most important class of antiresorptive agents available to treat diseases characterized by osteoclast-mediated bone resorption. These agents have a potent effect on the skeleton and are in common use for treatment of osteoporosis, Paget's disease, and metastatic bone disease in adults as well as in the treatment of pediatric disorders, such as osteogenesis imperfecta, Perthes’ disease, and fibrous dysplasia. Although initial investigations had demonstrated an acceptable safety profile of bisphosphonate drugs, but recently this has been questioned by some authors. In this article, we review the chemistry, pharmacokinetics, and pharmacodynamics of these agents in brief and the orthopedic applications as well as adverse effects in detail. How to cite this article Aggarwal S, Gahlot N, Saini UC, Dhillon MS. Bisphosphonates in Orthopedics: Evidencebased Review of Indications and Adverse Effects. J Postgrad Med Edu Res 2016;50(2):75-85.

scholarly journals THE RELEVANCE, BENEFITS AND CLINICAL PERSPECTIVES OF THE COMBINED TREATMENT OF OSTEOPOROSIS BASED ON BONE-ANABOLIC THERAPY

2015 ◽  
Vol 18 (2) ◽  
pp. 20-24
Author(s):  
L A Marchenkova ◽  
E Yu Martynova
Keyword(s):  
Combination Therapy ◽  
Hormonal Therapy ◽  
Combined Treatment ◽  
Evidence Based ◽  
Clinical Perspective ◽  
Treatment Combination ◽  
Treatment Of Osteoporosis ◽  
Anabolic Therapy ◽  
Osteoporosis Fracture ◽  
Subsequent Administration

Combination therapy of osteoporosis based on bone-anabolic and antiresorbtive agents has a great clinical perspective. An analysis of available publications shows that combination therapy is appropriate from the standpoint of increasing the effectiveness of treatment. Combination therapy can be executed as a simultaneous use of teriparatide with denosumab, raloxifene or hormonal therapy, and the subsequent administration of bisphosphonates, denosumab or raloxifene after treatment with teriparatide. The review presents the evidence-based data on the effect of combined and sequential regimens for osteoporosis fracture risk.

Sign in / Sign up

Export Citation Format

Share Document